M3 Group Joins MEDIROM Mother Labs' Series A Financing Round at JPY9 Billion (as of December 1, 2024, approximately USD $59,000,000) Pre-Money Valuation

Company Overview - MEDIROM Healthcare Technologies Inc. is involved in health-tech and has announced participation from M3, Inc. in its Series A equity financing round for its subsidiary, MEDIROM MOTHER Labs Inc. [1] - The Series A financing round is led by NFES Technologies Inc. with a pre-money valuation of JPY 9 billion [1] MOTHER Labs and Product Offering - MEDIROM MOTHER Labs focuses on health-tech, offering the "Specific Health Guidance Program" through the "Lav" health application and developing the 24/7 recharge-free MOTHER Bracelet smart tracker [5] - The MOTHER Bracelet is notable for being the world's first 24/7 recharge-free smart tracker, utilizing innovative technology to generate power from temperature differences [7] - The device records five basic health metrics: heart rate, calories burned, body surface temperature, step count, and sleep [7] M3, Inc. Background - M3, Inc. operates a global physician platform and is recognized for its significant member panel, which includes over 330,000 Japanese and more than 6.5 million global physicians [4]